Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Abbott Laboratories' (NYSE: ABT) January 2026 price pullback is making its stock look attractively valued. The move, driven more by market angst and fear than by any real weaknesses, seems to be a ...

Recent performance snapshot Abbott Laboratories (ABT) has seen mixed share performance recently, with a modest 0.2% move over the past day and a 1.3% gain over the past week, closing at $114.76. Over ...

Abbott Laboratories’ stock took a direct hit, wiping out nearly 10% of its market value following its Q4 earnings. Response? The CEO bought $2 million shares. Robert B. Ford, CEO of Abbott ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Abbott Laboratories (NYSE:ABT) reported new FreeDM2 trial results on its FreeStyle Libre continuous glucose monitoring system ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Disclosed on November 25, Eric Shroff, Senior Vice President at Abbott Laboratories (NYSE:ABT), executed a substantial insider sell as per the latest SEC filing. What Happened: Shroff's decision to ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.